AU2020346812A1 - Methods for alleviating pterygium-associated worry about eye appearance - Google Patents

Methods for alleviating pterygium-associated worry about eye appearance Download PDF

Info

Publication number
AU2020346812A1
AU2020346812A1 AU2020346812A AU2020346812A AU2020346812A1 AU 2020346812 A1 AU2020346812 A1 AU 2020346812A1 AU 2020346812 A AU2020346812 A AU 2020346812A AU 2020346812 A AU2020346812 A AU 2020346812A AU 2020346812 A1 AU2020346812 A1 AU 2020346812A1
Authority
AU
Australia
Prior art keywords
symptoms
patient reported
patient
reported signs
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020346812A
Other languages
English (en)
Inventor
Jinsong Ni
Scott Whitcup
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cloudbreak Therapeutics LLC
Original Assignee
Cloudbreak Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cloudbreak Therapeutics LLC filed Critical Cloudbreak Therapeutics LLC
Publication of AU2020346812A1 publication Critical patent/AU2020346812A1/en
Priority to AU2026202351A priority Critical patent/AU2026202351A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eye Examination Apparatus (AREA)
AU2020346812A 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance Abandoned AU2020346812A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026202351A AU2026202351A1 (en) 2019-09-10 2026-03-27 Methods for alleviating pterygium-associated worry about eye appearance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898401P 2019-09-10 2019-09-10
US62/898,401 2019-09-10
PCT/US2020/050150 WO2021050692A2 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026202351A Division AU2026202351A1 (en) 2019-09-10 2026-03-27 Methods for alleviating pterygium-associated worry about eye appearance

Publications (1)

Publication Number Publication Date
AU2020346812A1 true AU2020346812A1 (en) 2022-01-27

Family

ID=74870040

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020346812A Abandoned AU2020346812A1 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance
AU2026202351A Pending AU2026202351A1 (en) 2019-09-10 2026-03-27 Methods for alleviating pterygium-associated worry about eye appearance

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026202351A Pending AU2026202351A1 (en) 2019-09-10 2026-03-27 Methods for alleviating pterygium-associated worry about eye appearance

Country Status (10)

Country Link
US (1) US20220331310A1 (cg-RX-API-DMAC10.html)
EP (1) EP4027997A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022547401A (cg-RX-API-DMAC10.html)
KR (1) KR20220061147A (cg-RX-API-DMAC10.html)
CN (1) CN114340618A (cg-RX-API-DMAC10.html)
AU (2) AU2020346812A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021026662A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146811A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022000468A (cg-RX-API-DMAC10.html)
WO (1) WO2021050692A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
WO2013188268A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
CN108135737B (zh) * 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
EA035465B1 (ru) * 2015-06-09 2020-06-22 Байер Фарма Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
MX394623B (es) * 2016-02-04 2025-03-24 Ads Therapeutics Llc Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.
BR112018074450A2 (pt) * 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
WO2018064354A1 (en) * 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
JP7306697B2 (ja) * 2017-03-14 2023-07-11 オールジェネシス バイオセラピューティクス インコーポレイテッド ３－ｚ－［１－（４－（ｎ－（（４－メチル－ピペラジン－１－イル）－メチルカルボニル）－ｎ－メチル－アミノ）－フェニルアミノ）－１－フェニル－メチレン］－６－メトキシカルボニル－２－インドリノンの結晶形
KR20210013574A (ko) * 2018-05-25 2021-02-04 클라우드브레이크 테라퓨틱스, 엘엘씨 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법

Also Published As

Publication number Publication date
WO2021050692A3 (en) 2021-05-14
EP4027997A4 (en) 2023-10-11
MX2022000468A (es) 2022-02-03
KR20220061147A (ko) 2022-05-12
WO2021050692A2 (en) 2021-03-18
AU2026202351A1 (en) 2026-04-16
US20220331310A1 (en) 2022-10-20
CA3146811A1 (en) 2021-03-18
EP4027997A2 (en) 2022-07-20
BR112021026662A2 (pt) 2022-04-12
JP2022547401A (ja) 2022-11-14
JP2026090631A (ja) 2026-06-02
CN114340618A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
US12186424B2 (en) Compositions and methods for treating pterygium recurrence
Hain et al. Pharmacological treatment of vertigo
Talamo et al. Modulation of corneal wound healing after excimer laser keratomileusis using topical mitomycin C and steroids
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Iqbal et al. Standard cross‐linking versus photorefractive keratectomy combined with accelerated cross‐linking for keratoconus management: a comparative study
AU2026202351A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
Chanbour et al. Corneal cross-linking for keratoconus and post-LASIK ectasia and failure rate: a 3 years follow-up study
EP4257148A1 (en) Eyedrops for treating scleral thinning and screening method for therapeutic agent of scleral thinning
JP2024516003A (ja) 糖尿病網膜症および関連する状態を治療するための方法および組成物
Hass et al. Comparison between pilocarpine and timolol on diurnal pressures in open-angle glaucoma
JP2022547401A5 (cg-RX-API-DMAC10.html)
HK40068230A (en) Methods for alleviating pterygium-associated worry about eye appearance
Subasi et al. Macular safety and outcomes of accelerated cross-linking with a 7.2 J/cm² energy dose in keratoconus: A prospective case series
WO2022159533A1 (en) Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Juan et al. Pterygium Recurrence Prevention Utilizing Mitomycin C Washing, Case Series
HK40101374A (en) Compositions and methods for treating pterygium
Parida et al. Comparative clinical efficacy of bepotastine besilate versus olopatadine Hcl in seasonal allergic conjuctivitis
JPH05112450A (ja) 緑内障性の視神経病の治療のための薬剤組成およびその治療法
Kronemyer Surgical treatments range from cross-linking to keratoplasty when keratoconus progresses.
SUTPHIN Corneal Crosslinking with Riboflavin and Ultraviolet A. Part II. Clinical Indications and Results
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted